Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.
Matrix extracellular phosphoglycoprotein (MEPE) correlates with serum phosphorus prior to and during octreotide treatment and following excisional surgery in hypophosphatemic linear sebaceous nevus syndrome.
复制标题
基质细胞外磷酸糖蛋白(MEPE)与低磷线性皮脂痣综合征患者奥曲肽治疗前、治疗期间以及切除手术后的血清磷相关。
DOI:
10.1002/ajmg.a.32395
复制
发表时间:
2008
期刊:
影响因子:
--
通讯作者:
Fedarko,NealS
中科院分区:
文献类型:
--
作者:
Hoffman,WilliamH;Jain,Alka;Chen,Harold;Fedarko,NealS
Hereditary and acquired forms of hypophosphatemia result in metabolic bone disease with significant degrees of disability in children, adolescents and adults. Linear sebaceous nevus syndrome (LSNS) is a rare sporadic congenital phakomatosis of unknown etiology with a variable phenotype that includes hypophosphatemia [Carey et al., 1986].We have previously reported on a patient with LSNS and hypophosphatemia where the plasma phosphatonin, fibroblast growth factor-23 (FGF-23), was inversely related to the serum phosphorous prior to and after treatment with octreotide and excision surgery [Hoffman et al., 2005]. We now extend that observation by reporting on the positive correlation between serum phosphorus and matrix extracellular phosphoglycoprotein (MEPE), a downstream member of phosphate homeostasis and mineralization.